Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation

International Journal of Hematology

Volumn 92, Issue 1, 2010, Pages 144-151

  Furukawa, Tatsuo ^a   Kurasaki Ida, Tori ^b   Masuko, Masayoshi ^a   Tsukada, Nobuhiro ^b   Okazuka, Kiyoshi ^b   Sato, Naoko ^c   Yano, Toshio ^b   Abe, Takashi ^b   Momoi, Akihito ^b   Shibasaki, Yasuhiko ^b   Higashimura, Masutaka ^b   Karimata, Kaori ^b   Moriyama, Masato ^b   Kuroha, Takashi ^b   Takizawa, Jun ^b   Toba, Ken ^b   Narita, Miwako ^d   Fuse, Ichiro ^a   Takahashi, Masuhiro ^d   Aizawa, Yoshifusa ^b  

^a NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c NAGAOKA RED CROSS HOSPITAL   (Japan)

^d NIIGATA UNIVERSITY   (Japan)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Cyclosporine; Flow cytometry; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; CYTOKINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG MONITORING; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; PHARMACODYNAMICS; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; CELLS, CULTURED; CYCLOSPORINE; DRUG MONITORING; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PHARMACOKINETICS; T-LYMPHOCYTES; TIME FACTORS; YOUNG ADULT;

EID: 77955174355     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0610-0     Document Type: Article

References (23)

1. JL Ferrara KR Cooke T Teshima 2003 The pathophysiology of acute graft-versus-host disease Int J Hematol 78 181 187 10.1007/BF02983793 1:CAS:528:DC%2BD3sXovFymtro%3D 14604275
2. JL Ferrara JE Levine P Reddy E Holler 2009 Graft-versus-host disease Lancet 373 1550 1561 10.1016/S0140-6736(09)60237-3 1:CAS:528: DC%2BD1MXltlaqurk%3D 19282026
3. Devergie A. Graft vs. host disease. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T, editors. Haemopoietic stem cell transplantation, the EBMT Handbook 2004 revised edn. Forum Service Editore; 2004. p.162-77.
4. Chao NJ, Sullivan KM. Pharmacologic prevention of acute graft-versus-host disease. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas' hematopoietic cell transplantation, 4th edn. Blackwell Publishing; 2009. p. 1257-74.
5. T Ruutu D Niederwieser A Gratwohl JF Apperley 1997 A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT Bone Marrow Transpl 19 759 764 10.1038/sj.bmt.1700745 1:STN:280:DyaK2s3nvFOqsw%3D%3D
6. PF Halloran LM Helms L Kung J Noujaim 1999 The temporal profile of calcineurin inhibition by cyclosporine in vivo Transplantation 68 1356 1361 10.1097/00007890-199911150-00023 1:CAS:528:DyaK1MXotVCisbk%3D 10573076
7. R Sindhi MF LaVia E Paulling J McMichael G Burckart S Shaw, et al. 2000 Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine + rapamycin regimen Transplantation. 69 432 436 10.1097/00007890-200002150-00022 1:CAS:528:DC%2BD3cXhvVentrg%3D 10706056
8. BD Kahan (2004) Therapeutic drug monitoring of cyclosporine: 20 years of progress Transpl Proc. 36 (Suppl 2S) 378S 391S 10.1016/j.transproceed.2004.01. 091
9. B Nashan E Cole G Levy E Thervet 2002 Clinical validation studies of Neoral C(2) monitoring: a review Transplantation. 73 S3 S11 10.1097/00007890- 200205151-00002 12023607
10. G Levy E Thervet J Lake K Uchida 2002 Consensus on Neoral C(2) Expert Review in Transplantation (CONCERT) Group. Patient management by Neoral C(2) monitoring: an international consensus statement Transplantation 73 S12 S18 10.1097/00007890-200205151-00003 12023608
11. SR Knight PJ Morris 2007 The clinical benefits of cyclosporine C2-level monitoring a systematic review Transplantation 83 1525 1535 10.1097/01.tp. 0000268306.41196.2c 1:CAS:528:DC%2BD2sXmslynsro%3D 17589331
12. N Duncan C Craddock 2006 Optimizing the use of cyclosporin in allogeneic stem cell transplantation Bone Marrow Transpl 38 169 174 10.1038/sj.bmt.1705404 1:CAS:528:DC%2BD28XmvFyqsrk%3D
13. N Izumi T Furukawa N Sato K Okazuka N Tsukada T Abe, et al. 2007 Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A Bone Marrow Transpl 40 875 880 10.1038/sj.bmt.1705834 1:CAS:528:DC%2BD2sXhtFOju7zM
14. N Sato T Furukawa T Kuroha S Hashimoto M Masuko H Takahashi, et al. 2004 High-dose cytosine arabinoside and etoposide with total body irradiation as a preparatory regimen for allogeneic hematopoietic stem-cell transplantation in patients with acute lymphoblastic leukemia Bone Marrow Transpl 34 299 303 10.1038/sj.bmt.1704575 1:CAS:528:DC%2BD2cXmtFGjtrY%3D
15. LJ Picker MK Singh Z Zdraveski JR Treer SL Waldrop PR Bergstresser, et al. 1995 Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry Blood 86 1408 1419 1:CAS:528:DyaK2MXnsVCltrw%3D 7632949
16. M Fukudo I Yano S Masuda S Fukatsu T Katsura Y Ogura, et al. 2005 Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients Clin Pharmacol Ther 78 168 181 10.1016/j.clpt.2005.04.008 1:CAS:528:DC%2BD2MXnslyhtLk%3D 16084851
17. TD Batiuk F Pazderka J Enns L DeCastro PF Halloran 1995 Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible J Clin Invest 96 1254 1260 10.1172/JCI118159 1:CAS:528: DyaK2MXnvVGqtrc%3D 7657799
18. MP Hendriks NM Blijlevens AV Schattenberg DM Burger JP Donnelly 2006 Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients Bone Marrow Transpl 38 521 525 10.1038/sj.bmt.1705481 1:CAS:528:DC%2BD28Xps1Whtr8%3D
19. Y Nawa M Hara K Tanimoto K Nakase T Kozuka Y Maeda 2006 Single-dose daily infusion of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors Int J Hematol 83 159 163 10.1532/IJH97.05006 1:CAS:528:DC%2BD28XjtlCqsL4%3D 16513536
20. N Ogawa Y Kanda M Matsubara Y Asano M Nakagawa M Sakata-Yanagimoto, et al. 2004 Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion Bone Marrow Transpl 33 549 552 10.1038/sj.bmt.1704374 1:CAS:528:DC%2BD2cXhsV2ru78%3D
21. Y Kanda R Hyo T Yamashita K Fujimaki K Oshima M Onoda T Mori T Sakura M Tanaka M Sakai J Taguchi M Kurakawa A Maruta S Okamoto H Sakamaki Kanto Study Group of Cell Therapy (2006) Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor Am J Hematol 81 (11) 838 844 10.1002/ajh.20710
22. K Oshima Y Kanda H Nakasone S Arai N Nishimoto H Sato, et al. 2008 Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level Am J Hematol 83 226 232 10.1002/ajh.21087 1:CAS:528:DC%2BD1cXjsFyksr8%3D 17918253
23. International Neoral Renal Transplantation Study Group 2002 Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation Am J Transpl 2 148 156 10.1034/j.1600-6143.2002.020206.x